Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
The present invention provides substituted diamino-pyrimidine and substituted diamino-pyridine derivatives of Formula I; wherein X, Y, R 1 , R 2 , and Ar are defined herein, that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.
1. A compound of Formula I:
or a pharmaceutically acceptable salt thereof; wherein:
X is CH or N;
Y is CH or N;
provided that at least one of X and Y is N;
Ar is
R 1 is F, CN, C 1-3 haloalkyl, C 1-4 alkyl-NHC(═O)— or (C 1-4 alkyl) 2 NC(═O)—;
R 2 is methyl or ethyl;
R 3 is F, Cl, or methyl;
R 4 is Cl or methyl; and
Cy is phenyl or pyridyl, each of which is substituted by 0, 1, or 2 groups independently selected from fluoro and chloro groups.
2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein:
X is N and Y is N.
3. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 is CN.
4. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 2 is methyl.
5. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Cy is phenyl or pyridyl, each of which is substituted by 0, 1, or 2 fluoro groups.
6. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Cy is phenyl, which is substituted by 0, 1, or 2 fluoro groups.
7. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Cy is phenyl.
8. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Cy is 3-fluorophenyl.
9. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Cy is 2-fluorophenyl.
10. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Cy is 3,5-difluorophenyl.
11. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Cy is pyridyl, which is substituted by 0 or 1 fluoro groups.
12. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Ar is
13. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Ar is
14. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 3 is Cl or methyl.
15. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 3 is Cl.
16. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 3 is methyl.
17. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 4 is methyl.
18. The compound of claim 1 , wherein the compound is a compound of Formula II:
or a pharmaceutically acceptable salt thereof, wherein:
Ar is:
n is 0, 1, or 2;
R 3 is F, Cl, or methyl; and
R 4 is Cl or methyl.
19. The compound according to claim 1 which is 4-amino-6-({1-[5-chloro-8-(3-fluorophenyl)cinnolin-7-yl]ethyl}amino)-pyrimidine-5-carbonitrile or a pharmaceutically acceptable salt thereof.
20. The compound according to claim 1 which is 4-amino-6-({(1S)-1-[5-chloro-8-(3-fluorophenyl)cinnolin-7-yl]ethyl}amino)-pyrimidine-5-carbonitrile or a pharmaceutically acceptable salt thereof.
21. The compound according to claim 1 which is 4-amino-6-({1-[6-(3-fluorophenyl)-3-methyl-5-oxo-5H-[1,3]thiazolo[3,2-a]pyrimidin-7-yl] ethyl}amino)pyrimidine-5-carbonitrile or a pharmaceutically acceptable salt thereof.
22. The compound according to claim 1 which is 4-amino-6-({(1S)-1-[6-(3-fluorophenyl)-3-methyl-5-oxo-5H-[1,3]thiazolo[3,2-a]pyrimidin-7-yl]ethyl}amino)pyrimidine-5-carbonitrile or a pharmaceutically acceptable salt thereof.
23. A pharmaceutical composition comprising a compound according to claim 1 , or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.
24. A method of inhibiting an activity of a PI3K kinase, comprising contacting the kinase with a compound of claim 1 , or a pharmaceutically acceptable salt thereof.
25. A method of treating a disease in a human patient, wherein said disease is osteoarthritis, restenosis, atherosclerosis, arthritis, diabetic retinopathy, psoriasis, inflammation, pancreatitis, inflammatory bowel disease, myasthenia gravis, multiple sclerosis, or Sjöogren's syndrome, comprising administering to said human patient a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.
26. A method of treating an immune-based disease in a human patient, wherein said immune-based disease is rheumatoid arthritis, allergy, asthma, glomerulonephritis, lupus, or inflammation related to any of the aforementioned, comprising administering to said human patient a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.
27. A method of treating a cancer in a human patient, wherein said cancer is breast, prostate, colon, endometrial, brain, bladder, skin, uterus, ovary, lung, pancreatic, renal, gastric, or a hematological cancer, comprising administering to said human patient a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.
28. The method of claim 27 , wherein said hematological cancer is acute myeloblastic leukemia, chronic myeloid leukemia, or B cell lymphoma.
29. A method of treating a lung disease in a human patient, wherein said lung disease is acute lung injury (ALI) or adult respiratory distress syndrome (ARDS), comprising administering to said human patient a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.
30. The method of claim 24 , wherein said PI3K kinase is PI3Kδ.
31. The method of claim 27 , wherein said hematological cancer is B cell lymphoma.
32. The method of claim 27 , wherein said hematological cancer is diffuse large B cell lymphoma.